Health Care/Hospital

NOVOSENSE NST1002 facilitates accurate CGM measurement with glucose monitoring black technology

SHANGHAI, April 17, 2023 /PRNewswire/ -- Glucose monitoring is a key link in diabetes management. Currently, there are two main methods for self-monitoring of glucose in patients with diabetes, one is the traditional blood glucose Monitoring (BGM), and the other is continuous glucose monitoring (...

2023-04-18 09:28 1559

AACR 2023 | Ascentage Pharma Presents Results from Three Studies Underscoring Exploratory Efforts in Potential New Indications

SUZHOU, China and ROCKVILLE, Md., April 17, 2023 /PRNewswire/ -- Ascentage Pharma (6855.HK), a global biopharmaceutical company engaged in developing novel therapies for cancers, chronic hepatitis B (CHB), and age-related diseases, today announced that it had released results from three preclinic...

2023-04-18 09:08 1486

GC Biopharma celebrates 'World Hemophilia Day'

* To display a large media façade on its Yong-in R&D Center YONGIN, South Korea, April 17, 2023 /PRNewswire/ -- GC Biopharma (006280.KS), a leading provider of biopharmaceutical products inSouth Korea, takes part in a campaign to celebrate World Hemophilia Day. The company announced that a l...

2023-04-18 09:03 1475

USANA Malaysia Donates MYR 40,000 to Local Flood Relief

Donation in partnership with Suriana Welfare Society Malaysia KUALA LUMPUR, Malaysia, April 18, 2023 /PRNewswire/ -- Heavy flooding in Johor has led USANA Malaysia to donateMYR 40,000 in relief funds for those affected by this natural disaster. Beyond this donation, the company and its Associates...

2023-04-18 08:24 1785

Innovent Releases Final Analysis Results of ORIENT-16: the Phase 3 Study of Sintilimab in Combination with Chemotherapy for the First-Line Treatment of Gastric Cancer at the AACR Annual Meeting 2023

ROCKVILLE, Md. and SUZHOU, China, April 17, 2023 /PRNewswire/ -- Innovent Biologics, Inc. ("Innovent") (HKEX: 01801), a world-class biopharmaceutical company that develops, manufactures and commercializes high quality medicines for the treatment of oncology, autoimmune, metabolic, ophthalmology a...

2023-04-18 08:00 2006

Innovent Releases Final Analysis Results of ORIENT-16: the Phase 3 Study of Sintilimab in Combination with Chemotherapy for the First-Line Treatment of Gastric Cancer at the AACR Annual Meeting 2023

ROCKVILLE, Md. and SUZHOU, China, April 18, 2023 /PRNewswire/ -- Innovent Biologics, Inc. ("Innovent") (HKEX: 01801), a world-class biopharmaceutical company that develops, manufactures and commercializes high quality medicines for the treatment of oncology, autoimmune, metabolic, ophthalmology a...

2023-04-18 08:00 2382

Ocedurenone: A Novel Therapy for Uncontrolled Hypertension in Advanced Chronic Kidney Disease

PRINCETON, N.J., April 18, 2023 /PRNewswire/ -- EMJ Nephrology interviewed two World-renowned experts in nephrology and cardiology,George Bakris and Faiez Zannad, regarding the challenges of treating uncontrolled hypertension (uHTN) in patients with advanced chronic kidney disease (CKD), a large ...

2023-04-18 08:00 1887

Innovent Announces Updated Data of Phase 1 Clinical Trial for IBI351 (KRAS[G12C] Inhibitor) as Monotherapy for Solid Tumors at the AACR Annual Meeting 2023

ROCKVILLE, Md. and SUZHOU, China, April 18, 2023 /PRNewswire/ -- Innovent Biologics, Inc. ("Innovent") (HKEX: 01801), a world-class biopharmaceutical company that develops, manufactures and commercializes high quality medicines for the treatment of oncology, autoimmune, metabolic, ophthalmolog...

2023-04-18 08:00 2492

Shanghai Cellular Biopharmaceutical Group presents first data from Phase I trial evaluating a novel CAR-T in advanced liver cancer at AACR Annual Meeting

Promising anti-tumor activity reported for C-CAR031, a novel Glypican 3 (GPC3)-targeting cell therapy designed by AstraZeneca SHANGHAI, April 18, 2023 /PRNewswire/ -- Shanghai Cellular Biopharmaceutical Group Ltd. (the Company, or Shanghai Cellular Bio), a company engaged in the drug development...

2023-04-18 04:15 1727

Promising Efficacy of AT101 CAR-T for Blood Cancer

SEOUL, South Korea, April 17, 2023 /PRNewswire/ -- AbClon, a South Korean biotech firm, presented non-clinical and phase 1 interim results of its AT101 novel CAR-T therapy at the annual 2023 AACR conference. AT101 targets the CD19 protein for treatment of blood cancer. AT101 demonstrated superio...

2023-04-18 02:00 1507

EXCHANGE OFFER DECLARED UNCONDITIONAL

KAISERAUGST, Switzerland, HEERLEN, Netherlands and GENEVA, April 18, 2023 /PRNewswire/ -- THIS PRESS RELEASE IS NOT FOR GENERAL RELEASE, PUBLICATION OR DISTRIBUTION, IN WHOLE OR IN PART, IN OR INTO, DIRECTLY OR INDIRECTLY,THE UNITED STATES OR ANY OTHER JURISDICTION WHERE SUCH RELEASE, PUBLICATIO...

2023-04-18 01:51 1913

Waterdrop Files Annual Report on Form 20-F for Fiscal Year 2022

BEIJING, April 17, 2023 /PRNewswire/ -- Waterdrop Inc. ("Waterdrop", the "Company" or "we") (NYSE: WDH), a leading technology platform dedicated to insurance and healthcare service with a positive social impact, today announced that it filed its annual report on Form 20-F for the fiscal year ende...

2023-04-17 20:24 2288

Antengene Announces Five Presentations at the 2023 American Association for Cancer Research Meeting

* Five posters showcased progress with multiple preclinical and clinical programs, includingATG-008 (mTORC1/2 inhibitor), ATG-017 (ERK1/2 inhibitor), ATG-037 (CD73 inhibitor), ATG-031 (anti-CD24 monoclonal antibody) and ATG-034 (LILRB4 antagonist antibody) * Clinical results showed promising ...

2023-04-17 20:22 2015

Orion Health launches Orchestral - a once in a generation giant leap forward for health data

Orchestral reimagines the aggregation of data and how it is used in healthcare in the modern machine learning era. AUCKLAND, New Zealand, April 17, 2023 /PRNewswire/ -- The Orchestral health intelligence platform, announced at HIMSS23, is the biggest step forward in health data since the advent ...

2023-04-17 20:00 1512

Asieris Releases 2022 Annual Report: Makes Steady Progress in its Clinical Development, Global Expansion to Treat Genitourinary Tumors, and Implementing its Commercialization Strategy to Provide Integrated Diagnosis-to-Treatment Solutions

SHANGHAI, April 17, 2023 /PRNewswire/ -- Asieris Pharmaceuticals(688176.SH), a global biopharma company specializing in the discovery, development and commercialization of innovative drugs that treat genitourinary (GU) tumors and other related diseases, today released its 2022 annual report. Whil...

2023-04-17 18:30 1774

Telix Reports Q1 2023 Financial Results: Delivers First $100M Revenue Quarter

MELBOURNE, Australia, April 17, 2023 /PRNewswire/ -- Telix Pharmaceuticals Limited (ASX: TLX, Telix, the Company) today issues its Appendix 4C quarterly cash flow statement and accompanying Activities Report for the quarter ended31 March 2023 (Q1 2023). All figures are in AUD$ unless otherwise st...

2023-04-17 18:15 2030

World Hemophilia Day 2023 - "Access for All: Prevention of bleeds as the global standard of care"

MONTREAL, April 17, 2023 /PRNewswire/ -- April 17, 2023 is World Hemophilia Day. The theme of the event this year is "Access for All: Prevention of bleeds as the global standard of care". Building on last year's theme, the call to action for the community in 2023 is to come together and advocate ...

2023-04-17 17:00 1363

Bassem Elmankabadi, M.D. joins Foresee Pharmaceuticals as a Senior Vice President of Clinical Development

TAIPEI, April 17, 2023 /PRNewswire/ -- Foresee Pharmaceuticals Co., Ltd. (6576.TWO) ("Foresee"), announces today thatBassem Elmankabadi, M.D. joins Foresee as a Senior Vice President of Clinical Development. Dr. Bassem Elmankabadi is a Board Certified Surgeon with over 17 years of clinical backg...

2023-04-17 16:50 1390

CT Event Asia to host the 3rd Annual ASEAN Healthcare Transformation Summit

KUALA LUMPUR, Malaysia, April 17, 2023 /PRNewswire/ -- This year, CT Asia is all set to bring you the 3rd Annual ASEAN Healthcare Transformation Summit, an exclusive platform for healthcare professionals, aiming to educate the masses on trending innovative technologies designed to personalize hea...

2023-04-17 15:27 1928

Late-Breaking Research - Alphamab Oncology Presents Preclinical Results of KN052 at AACR 2023

SUZHOU, China, April 17, 2023 /PRNewswire/ -- Alphamab Oncology (stock code: 9966.HK) announced that the preclinical result of KN052 (PD-L1/OX40 bispecific antibody) were presented as a poster at the Late-Breaking Research session of the AACR Annual Meeting 2023 (AACR 2023). The AACR Annual Meet...

2023-04-17 14:01 1862
1 ... 172173174175176177178 ... 809